Cherenkov luminescence imaging is a fast and relevant preclinical tool to assess tumour hypoxia in vivo.
Fiche publication
Date publication
décembre 2018
Journal
EJNMMI research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr COLLIN Bertrand, Dr DECREAU Richard, Dr BELLAYE Pierre-Simon
Tous les auteurs :
Desvaux E, Courteau A, Bellaye PS, Guillemin M, Drouet C, Walker P, Collin B, Decréau RA
Lien Pubmed
Résumé
Molecular imaging techniques visualise biomarkers for both drug development and personalised medicine. In this field, Cherenkov luminescence imaging (CLI) seems to be very attractive by allowing imaging with clinical PET radiotracers with high-throughput capabilities. In this context, we developed a fast CLI method to detect tumour hypoxia with F-fluoromisonidazole (FMISO) for drug development purposes.
Mots clés
18F-Fluoromisonidazole (FMISO), BOLD, Cherenkov luminescence imaging (CLI), Colon cancer, Hypoxia, Magnetic resonance imaging, Positron emission tomography (PET)
Référence
EJNMMI Res. 2018 Dec 20;8(1):111